Reply: Fetal safety of dydrogesterone: clarifying the role of pharmacovigilance

Laurent Chouchana, Alexandra Henry, Mathilde Bourdon, Chloé Maignien, Charles Chapron, Jean-Marc Treluyer, Jean Guibourdenche, Piétro Santulli
Human reproduction open · 2025 · vol. 2025(3) , pp. hoaf031 · doi:10.1093/hropen/hoaf031 · PMID:40497084 · PMC12151319
other OA: gold CC-BY-4.0
📄 Open PDF View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This paper clarifies the role of pharmacovigilance in assessing the fetal safety of dydrogesterone, addressing questions raised by previous research.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
pubmed
last seen: 2026-05-20T00:31:22.508620+00:00
unpaywall
last seen: 2026-05-15T02:00:00.661756+00:00
License: CC-BY-4.0 · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine